Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Sep 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called semaglutide (also known as Rybelsus) affects certain hormones in the body, particularly cortisol, which is important for managing stress. The researchers want to understand how this medication influences the hypothalamo-pituitary-adrenal (HPA) axis, which is the system that controls our response to stress. The trial is looking for healthy male volunteers aged between 18 and 60 who do not take any regular medications and have a body mass index (BMI) between 18.5 and 30.

If you qualify and choose to participate, you will receive a single dose of semaglutide and then have your hormone levels monitored. It’s important to note that if you have participated in another clinical trial within the last 30 days, engaged in vigorous exercise or consumed alcohol within 24 hours before the study, or have a history of certain medication use, you may not be eligible. This study is still recruiting participants, so if you’re interested and meet the criteria, you could contribute to valuable research on adrenal function.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Healthy male volunteers aged 18-60 years
• • BMI 18.5-30 kg/m2
• • No regular medication
• Exclusion Criteria:
• • participation in a trial with investigational drugs within 30 days
• • vigorous physical exercise within 24 hours before the study participation
• • alcohol intake within 24 hours before the study participation
• • a history of intake of glucocorticoids or GLP-1 RA within the last 8 weeks.
• • Known allergy towards GLP-1 RA